DOVER, DE--(Marketwired - Oct 4, 2017) - Rocky Mountain Ayre, Inc. (
Dr. Sullivan is a Molecular Pharmacologist with over 25 years experience producing scientific opportunities. As the managing partner for the last decade of Sullivan Rajan LLC, he has identified preclinical and clinical assets with untapped commercial opportunity and assembled a team of investors, scientists, consultants, bankers and pharmaceutical partners to bring drugs to patients. Focusing on overcoming the twin drawbacks that plague oncology treatments -- toxicity and risk of relapse -- Dr. Sullivan has helped guide many products into clinical development and jumpstarted molecular surgery programs at major pharmaceutical companies. His current focus is on financing scientific innovation in areas of the world currently overlooked by established biotechnology venture funds. He holds an M.B.A. in Finance and Accounting from Columbia Business School and a Ph.D. in Molecular Pharmacology from The Cancer Institute of New Jersey, Rutgers Medical School and Rutgers School of Biomedical Sciences.
Timothy Ayre, President of RMTN, says, "We welcome Dr. Greg Sullivan to the company. His financial and scientific experience will empower us to achieve our twin desires to build balance sheet value and leverage financial and biotechnology innovations."
This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.